Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, AUG. 12, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (COMPASS) (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS TO TREAT MULTIPLE HUMAN DISEASES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 33,290,000 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $3.00 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 6,710,000 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $2.9999 PER PRE-FUNDED WARRANT TO PURCHASE ONE SHARE OF THE COMMON STOCK, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE FOR THE COMMON STOCK LESS THE $0.0001 PER SHARE EXERCISE PRICE FOR EACH SUCH PRE-FUNDED WARRANT. THE GROSS PROCEEDS FROM THE OFFERING TO COMPASS ARE EXPECTED TO BE APPROXIMATELY $120 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT AUGUST 14, 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS. IN ADDITION, COMPASS HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO 6,000,000 ADDITIONAL SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNT.

COMPASS THERAPEUTICS ANNOUNCES PRICING OF UPSIZED $120 MILLION PUBLIC OFFERING

BOSTON, AUG. 12, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (COMPASS) (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS TO TREAT MULTIPLE HUMAN DISEASES, TODAY ANNOUNCED THE LAUNCH OF AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. ALL SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS TO BE SOLD IN THE OFFERING WILL BE OFFERED BY COMPASS. COMPASS ALSO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE ADDITIONAL SHARES OF ITS COMMON STOCK OFFERED IN THE PUBLIC OFFERING UNDER THE SAME TERMS AND CONDITIONS. THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR THE ACTUAL SIZE OR TERMS OF THE OFFERING.

COMPASS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING

BOSTON, AUG. 11, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS, TODAY REPORTED SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDED A BUSINESS UPDATE ON ITS CLINICAL AND PRE-CLINICAL PROGRAMS.

COMPASS THERAPEUTICS REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BOSTON, AUG. 08, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS, WILL RELEASE ITS FINANCIAL RESULTS FOR THE QUARTER ENDEDJUNE 30, 2025 AND HOST A WEBCAST AND CONFERENCE CALL TO PROVIDE AN UPDATE ON THE ONGOING TOVECIMIG PHASE 2/3 STUDY, CLINICAL DATA FOR CTX-8371 AND PRECLINICAL DATA FOR CTX-10726, ONMONDAY, AUGUST 11, 2025, AT8:00 A.M. ET.

COMPASS THERAPEUTICS TO PRESENT SECOND QUARTER FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON AUGUST 11, 2025

BOSTON, MAY 28, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE TAKING PLACE JUNE 3-5, 2025. FIRESIDE CHAT DETAILS DATE: THURSDAY, JUNE 5, 2025TIME: 11:05  11:35 AM ETWEBCAST LINK:HTTPS://WSW.COM/WEBCAST/JEFF319/CMPX/1867328 VIRTUAL/REPLAY AVAILABILITY:THE FIRESIDE CHAT WILL BE ARCHIVED FOR 90 DAYS ON COMPASS'EVENTSPAGE.

COMPASS THERAPEUTICS TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

TOVECIMIG (DLL4 X VEGF-A BISPECIFIC ANTIBODY) MET THE PRIMARY ENDPOINT IN THE ONGOING RANDOMIZED PHASE 2/3 STUDY IN PATIENTS WITH BILIARY TRACT CANCER (BTC). ACHIEVED A 17.1% OVERALL RESPONSE RATE (ORR), INCLUDING ONE COMPLETE RESPONSE, COMPARED TO A 5.3% ORR FOR PACLITAXEL ALONE, IN PATIENTS WITH BTC TREATED IN THE SECOND-LINE SETTING.

COMPASS THERAPEUTICS REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BOSTON, MAY 06, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING INVESTOR EVENTS DURING THE MONTH OF MAY. DETAILS ARE AS FOLLOWS: THE CITIZENS LIFE SCIENCES CONFERENCE LOCATION: NEW YORK, NY DATE: THURSDAY, MAY 8, 2025 TIME: 1:30 PM ET WEBCAST LINK: HTTPS://WSW.COM/WEBCAST/JMP65/CMPX/1692592 H.C.

COMPASS THERAPEUTICS TO PARTICIPATE IN UPCOMING MAY INVESTOR EVENTS

CTX-471 MONOTHERAPY DEMONSTRATED EFFICACY IN MULTIPLE MURINE MODELS, INCLUDING MODELS HIGHLY RESISTANT TO IMMUNE CHECKPOINT INHIBITORS. COMBINING CTX-471 WITH TOVECIMIG (CTX-009) MARKEDLY INCREASED ANTI-TUMOR EFFICACY IN THESE MODELS.

COMPASS THERAPEUTICS PRESENTS DATA ON ENHANCED EFFICACY OF CTX-471 IN COMBINATION WITH TOVECIMIG IN CHECKPOINT-REFRACTORY MODELS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING

BOSTON, APRIL 21, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS, ANNOUNCED THE FIRST PATIENT HAS BEEN DOSED IN AN INVESTIGATOR SPONSORED TRIAL (IST) TO EVALUATE TOVECIMIG (CTX-009, A DLL4 X VEGF-A BISPECIFIC ANTIBODY) FOR THE FIRST TIME IN THE FRONT-LINE SETTING FOR PATIENTS WITH BILIARY TRACT CANCER (BTC). THE IST IS BEING CONDUCTED AT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER.

COMPASS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN AN INVESTIGATOR SPONSORED TRIAL OF TOVECIMIG IN THE FIRST-LINE SETTING FOR PATIENTS WITH BILIARY TRACT CANCER

BOSTON, APRIL 02, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS TO TREAT MULTIPLE HUMAN DISEASES, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT AT THE STIFEL 2025 VIRTUAL TARGETED ONCOLOGY FORUM TAKING PLACE APRIL 8-9, 2025.

COMPASS THERAPEUTICS TO PARTICIPATE IN THE STIFEL 2025 VIRTUAL TARGETED ONCOLOGY FORUM

TOVECIMIG (A DLL4 X VEGF-A BISPECIFIC ANTIBODY) IN COMBINATION WITH PACLITAXEL ACHIEVED A 17.1% OVERALL RESPONSE RATE (ORR), INCLUDING ONE COMPLETE RESPONSE, COMPARED TO 5.3% ORR FOR PACLITAXEL ALONE, IN PATIENTS WITH BILIARY TRACT CANCER (BTC) TREATED IN THE SECOND-LINE SETTING. THE DIFFERENCE IN ORR BETWEEN THE TWO TREATMENT ARMS, THE PRIMARY ENDPOINT OF THE STUDY, WAS STATISTICALLY SIGNIFICANT (P=0.031), AND ALL RESPONSES HAVE BEEN CONFIRMED BY BLINDED INDEPENDENT CENTRAL RADIOLOGY REVIEW.

TOVECIMIG (CTX-009) MEETS PRIMARY ENDPOINT IN THE ONGOING RANDOMIZED PHASE 2/3 STUDY IN PATIENTS WITH BILIARY TRACT CANCER

WEBCAST SCHEDULED FOR TUESDAY, APRIL 1, 2025 AT 8:00 AM ET. BOSTON, MARCH 31, 2025 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS TO TREAT MULTIPLE HUMAN DISEASES, ANNOUNCED IT WILL HOST A WEBCAST ON TUESDAY, APRIL 1, 2025 AT 8:00 AM ET TO REVIEW TOP-LINE CLINICAL DATA FROM ITS ONGOING PHASE 2/3 COMPANION-002 CLINICAL TRIAL ASSESSING TOVECIMIG (A DLL4 X VEGF-A BISPECIFIC ANTIBODY) IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED BILIARY TRACT CANCER (BTC).

COMPASS THERAPEUTICS TO HOST WEBCAST HIGHLIGHTING TOP-LINE CLINICAL DATA FROM THE ONGOING RANDOMIZED PHASE 2/3 STUDY EVALUATING TOVECIMIG IN PATIENTS WITH BILIARY TRACT CANCER

TOP-LINE PHASE 2/3 DATA READOUT FOR COMPANION-002, EVALUATING TOVECIMIG (CTX-009 - A DLL4 X VEGF-A BISPECIFIC ANTIBODY) IN PATIENTS WITH BILIARY TRACT CANCER (BTC), IS ON TRACK FOR THE END OF THE FIRST QUARTER 2025. SUPPORTED INITIATION OF AN INVESTIGATOR SPONSORED STUDY (IST) EVALUATING TOVECIMIG IN PATIENTS WITH BTC IN THE FIRST-LINE SETTING, WITH PATIENT DOSING EXPECTED IN THE FIRST QUARTER 2025.

Compass Therapeutics, Inc.

CMPX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Compass Therapeutics, Inc.

CMPX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CMPX